Nonviral gene therapy in vivo with PAM-RG4/ apoptin as a potential brain tumor therapeutic

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 821-834

  An, Songhie ^a   Nam, Kihoon ^a   Choi, Sunghyun ^a   Bai, Cheng Z ^a   Lee, Yan ^a   Park, Jong Sang ^a  

^a Seoul National University   (South Korea)

Author keywords

Apoptin; Apoptosis; Malignant glioma; Nonviral gene therapy; PAM RG4

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; APOPTIN; CASPASE 3; EOSIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FAS ASSOCIATED DEATH DOMAIN PROTEIN; HEMATOXYLIN; PLASMID DNA; POLYAMIDOAMINE G4 ARGININE CONJUGATE; POLYETHYLENEIMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTIN GENE; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CELL VIABILITY; COMPLEX FORMATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; EMBRYO; ENZYME ACTIVITY; GENE; GENE EXPRESSION; GENETIC TRANSFECTION; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NICK END LABELING; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PROTEIN PROTEIN INTERACTION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE; TUMOR VOLUME; TUMOR XENOGRAFT;

APOPTIN; APOPTOSIS; MALIGNANT GLIOMA; NONVIRAL GENE THERAPY; PAM-RG4;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARGININE; BRAIN NEOPLASMS; CAPSID PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; DENDRIMERS; GENETIC THERAPY; HUMANS; IN SITU NICK-END LABELING; MICE; MICE, NUDE; RANDOM ALLOCATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84874424824     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S39072     Document Type: Article

References (34)

1. Bernstein M, Berger MS. Neuro-oncology: the essentials, 2nd ed. New York, NY: Thieme; 2008.
2. Rainov NG, Ren H. Gene therapy for human malignant brain tumors. Cancer J. 2003;9(3):180-188.
3. Wakabayashi T, Iwami K, Natsume A. Gene therapy for high-grade glioma. Neurol Med-Chir. 2010;50(9):727-736.
4. Candolfi M, Xiong W, Yagiz K, et al. Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics. Proc Natl Acad Sci U S A. 2010;107(46):20021-20026.
5. Sheridan C. Gene therapy finds its niche (2011;29:121). Nat Biotechnol. 2011;29(5):459-459.
6. Lee JK, Kim ID, Lim CM, et al. Neuroprotection by biodegradable PAMAM ester (e-PAM-R)-mediated HMGB1 siRNA delivery in primary cortical cultures and in the postischemic brain. J Control Release. 2010;142(3):422-430.
7. Park JS, Nam HY, Hahn HJ, et al. Evaluation of generations 2, 3 and 4 arginine modified PAMAM dendrimers for gene delivery. Int J Pharm. 2008;363(1-2):199-205.
8. Park JS, Kim TI, Bai CZ, Nam K. Comparison between arginine conjugated PAMAM dendrimers with structural diversity for gene delivery systems. J Control Release. 2009;136(2):132-139.
9. Sheridan C. Gene therapy finds its niche. Nat Biotechnol. 2011;29(2): 121-128.
10. Engelhard HH. Gene therapy for brain tumors: The fundamentals. Surg Neurol. 2000;54(1):3-9.
11. Maddika S, Booy EP, Johar D, Gibson SB, Ghavami S, Los M. Cancerspecific toxicity of apoptin is independent of death receptors but involves the loss of mitochondrial membrane potential and the release of mitochondrial cell-death mediators by a Nur77-dependent pathway. J Cell Sci. 2005;118(19):4485-4493.
12. Lin BZ, Kolluri SK, Lin F, et al. Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3. Cell. 2004;116(4):527-540.
13. Qu S, Sun J, Yan Y, et al. PTD4-apoptin protein therapy inhibits tumor growth in vivo. Int J Cancer. 2009;124(12):2973-2981.
14. Choi JS, Nam K, Park JY, Kim JB, Lee JK, Park JS. Enhanced transfection efficiency of PAMAM dendrimer by surface modification with L-arginine. J Control Release. 2004;99(3):445-456.
15. Engebraaten O, Hjortland GO, Juell S, Hirschberg H, Fodstad O. Intratumoral immunotoxin treatment of human malignant brain tumors in immunodeficient animals. Int J Cancer. 2002;97(6):846-852.
16. Gorgoulis V, Aninos D, Mikou P, et al. Expression of EGF, TGF alpha and EGFR in squamous cell lung carcinomas. Anticancer Res. 1992;12(4):1183-1188.
17. Berger MS, Gullick WJ, Greenfield C, Evans S, Addis BJ, Waterfield MD. Epidermal growth-factor receptors in lung-tumors. J Pathol. 1987;152(4):297-307.
18. Siegal GP, Wang D, Stockard CR, et al. Immunohistochemistry in the evaluation of neovascularization in tumor xenografts. Biotech Histochem. 2008;83(3-4):179-189.
19. Niidome T, Okuda T, Sugiyama A, Aoyagi H. Characters of dendritic poly((L)-lysine) analogues with the terminal lysines replaced with arginines and histidines as gene carriers in vitro. Biomaterials. 2004;25(3):537-544.
20. Fischer D, Li YX, Ahlemeyer B, Krieglstein J, Kissel T. In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. Biomaterials. 2003;24(7):1121-1131.
21. Muller H, Brock M, Ernst H. Long-term survival and recurrence-free interval in combined surgical, radiotherapy and chemotherapy of malignant brain gliomas. Clin Neurol Neurosur. 1985;87(3):167-171.
22. Oldfield EH, Ram Z, Culver KW, et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med. 1997;3(12):1354-1361.
23. Begley DJ. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Therapeut. 2004;104(1):29-45.
24. Los M, Panigrahi S, Rashedi I, et al. Apoptin, a tumor-selective killer. Biochim Biophys Acta. 2009;1793(8):1335-1342.
25. Kim ID, Shin JH, Kim SW, et al. Intranasal delivery of HMGB1 siRNA confers target gene knockdown and robust neuroprotection in the postischemic brain. Mol Ther. 2012;20(4):829-839.
26. Miller CR, Buchsbaum DJ, Reynolds PN, et al. Differential susceptibility of primary and established human glioma cells to adenovirus infection: Targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res. 1998;58(24): 5738-5748.
27. Wikstrand CJ, McLendon RE, Friedman AH, Bigner DD. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res. 1997;57(18): 4130-4140.
28. Libermann TA, Nusbaum HR, Razon N, et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human-brain tumors of glial origin. Nature. 1985;313(5998): 144-147.
29. Libermann TA, Razon N, Bartal AD, Yarden Y, Schlessinger J, Soreq H. Expression of epidermal growth factor receptors in human brain tumors. Cancer Res. 1984;44(2):753-760.
30. Wong AJ, Bigner SH, Bigner DD, Kinzler KW, Hamilton SR, Vogelstein B. Increased expression of the epidermal growth-factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci U S A. 1987;84(19):6899-6903.
31. Argiris K, Panethymitaki C, Tavassoli M. Naturally occurring, tumor-specific, therapeutic proteins. Exp Biol Med. 2011;236(5): 524-536.
32. Seralini GE, Benachour N. Glyphosate formulations induce apoptosis and necrosis in human umbilical, embryonic, and placental cells. Chem Res Toxicol. 2009;22(1):97-105.
33. Abu-Qare AW, Abou-Donia MB. Biomarkers of apoptosis: Release of cytochrome c, activation of caspase-3, induction of 8-hydroxy-2′-deoxyguanosine, increased 3-nitrotyrosine, and alteration of p53 gene. J Toxicol Env Heal B. 2001;4(3):313-332.
34. Guelen L. Development of an Efficient and Tumor Specific Apoptosis Inducing System Using Viral Gene Products [PhD thesis]. London, UK: University of London; 2004.